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free survival (PFS) and/or overall survival (OS) as reported outcomes and to create 
a RCT network accordingly. Fixed and random effects FP models of first/second 
order were applied on these data and tested for goodness of fit using deviance 
information criteria. Finally, the best fitting model was used to estimate the hazard 
function, median PFS, median OS and uncertainty of treatment effect. Results: 
Literature review found 8 RCTs and 5 RCTs which reported PFS and OS respec-
tively, for 7 different mRCC treatments (interferon-alfa (IFN), bevacizumab+IFN, 
temisrolimus+bevacizumab, sunitinib, pazopanib, cediranib, placebo). The best fit-
ting FP model was second order random effect model for both, PFS and OS NMA. 
Hazard functions varied significantly. Estimated median PFS was the longest with 
sunitinib (10.8 months; 95% credible interval (CI): 9.5-11.8), followed by pazopanib 
and temsirolimus+bevacizumab. Similarly, sunitinib was estimated with the 
longest median OS (28.8 months; 95% CI: 25.7-31.0) followed by pazopanib and 
bevacizumab+IFN. ConClusions: Synthesis of NMA evidence for 1LmRCC treat-
ments identified sunitinib to be the treatment with favourable PFS and OS. When 
dealing with multiple sources, hazards proportionality assumption is violated, and 
proposed method should be the method of choice.
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objeCtives: Network meta-analysis (NMA) is widely used to compare multiple 
interventions of interest when head-to-head comparisons of active treatments are 
not available. Most NMAs pool data from randomised controlled trials (RCTs) on a 
single clinical outcome. However, in the case of chronic diseases such as rheumatoid 
arthritis (RA), outcomes are often reported at different time points and long-term 
real-world data (RWD) is routinely collected as part of national registries. Evaluation 
of models for the inclusion of different time measures in NMA, especially from both 
a regulatory and reimbursement perspective, is thus warranted and is considered 
here. Methods: RCTs and observational studies evaluating biological agents in RA 
were searched using standard filters and electronic databases. Networks of RCTs 
were supplemented with RWD to include outcomes extracted for as many time 
points as possible. Multivariate NMA models were extended to incorporate repeated 
measures, adjusting for correlation between time points and bias of RWD. Sensitivity 
and scenario analyses were performed to test different network sizes, correlation 
structures and bias adjustments. Results: Addition of RWD and studies reporting 
treatment effects at multiple time points significantly increased the evidence base 
for NMA in RA. The inclusion of RWD led to a reduction in the level of uncertainty 
around most of the effect estimates. Furthermore, the additional evidence from 
multiple times has potential of reducing uncertainty by ‘borrowing’ evidence and 
giving a fuller view of treatment effect over time, not just at a specific single time 
point. ConClusions: Initial evaluation of these models in NMA indicates that 
extending an evidence base to include repeated measures and RWD maximises 
study network sizes and can significantly impact the level of uncertainty in treat-
ment effects. Further investigation of correlation and bias modelling is warranted, 
as too is the application of new NMA fractional polynomials model to RA.
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objeCtives: Using simulated annealing (SA) to inform the economic evaluation 
of treatment sequences for rheumatoid arthritis (RA). Methods: A discrete event 
simulation (DES) model was built to estimate lifetime costs and Quality Adjusted 
Life Years (QALYs) of alternative sequences for the treatment of patients with 
severe RA. Thirteen Disease Modifying Anti-Rheumatic Drugs (DMARDs) can be 
used sequentially, with a theoretical maximum size of the decision space of over 
10 billion unique sequences. This problem can be formulated as an optimisation 
problem – finding the treatment sequence that maximises net monetary benefit 
(NMB). However, it was not feasible to evaluate the NMB of every treatment sequence 
in the decision space. SA, a stochastic optimisation algorithm, was used to identify 
a sequence that was optimal, or near optimal. Given the evaluation of the NMB 
of some particular sequence by the DES model , the SA algorithm then selects a 
“nearby” sequence to evaluate. Better solutions are accepted, and worse solutions 
are sometimes accepted with a probability reducing as the algorithm progresses. 
This attempts to prevent the optimiser from getting stuck in a local optimum. 
Comprehensive tuning of the parameters of the SA algorithm was undertaken, 
and scenario analysis was performed. Results: At a willingness to pay of £30,000 
per QALY gained, the best performing sequence found was exclusively composed of 
conventional DMARDs. At £50,000 per QALY gained, the best performing sequence 
began with conventional DMARDs for the first four treatment lines, before beginning 
biologic DMARD treatment. The results were consistent when re-run, and when 
alternative specifications of the SA algorithm were used. ConClusions: SA is a 
commonly used optimisation method, but it has rarely been applied in HTA. In this 
instance, SA performed well and may be an appropriate method for health resource 
allocation decision-making where there is a large decision space.
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objeCtives: The aim of this study is to compare the usefulness of two prom-
ising alternative modeling techniques, Timed Automata (TA) originating from 
65. Similarly, a 5-point lower MCS score among those with depression was associated 
with a 10% increase in MEs at age 25 but 4% at age 55. ConClusions: Differences in 
SF-12v2 scores, particularly PCS, had substantial impact on MEs, allowing enhanced 
interpretation of intervention-based improvements in SF-12v2 scores. In arthritis 
and depression, age significantly impacted the association between HRQL and MEs.
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objeCtives: Perceived and observed insensitivity of the EQ-5D instrument in cer-
tain clinical areas has led to the development of condition specific preference based 
instruments, also for Multiple Sclerosis (MS). It is uncertain how these instruments 
perform in economic evaluations. This study investigates the effect on the incre-
mental cost-effectiveness ratio (ICER) of using MS specific utility values rather than 
generic utility values. Methods: A Markov model with a lifetime time horizon 
comparing symptom management with subcutaneous glatiramer acetate was based 
on a previously published study. The model has four EDSS health states and two 
relapse states, a one month cycle, accounts for age specific background mortality 
and discontinuation of therapy. Costs and effects were discounted with 3%. For 
this study, QALYs were calculated with utility values from the MSIS-PBM, a sensi-
tive condition specific utility instrument based on a Time Trade-off valuation of 
MSIS-29, and EQ-5D utility values. Values were both taken from the UK risk sharing 
scheme. Deterministic and Monte Carlo simulation based probabilistic sensitivity 
analyses were used to assess impact on ICER. Results: The mean ICER after 5000 
simulations was USD 291.545 using MS specific utilities, and 180.633 using EQ-5D 
based utilities. ConClusions: This study used condition specific and generic util-
ity values in a hypothetical Markov model for relapsing remitting MS patients and 
showed that the incremental cost-effectiveness ratio was 60% higher when applying 
the condition specific utilities. Contrary to what might be expected, the condition 
specific utility instrument was not better at demonstrating treatment value than 
the generic EQ-5D.
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objeCtives: Adherent type 2 diabetes (T2DM) patients are more likely to have 
good glycaemic control than non-adherent patients, potentially resulting in bet-
ter outcomes. We investigated the association between the number of glucose-
lowering therapies, adherence and their impact on glycaemic control and quality 
of life (QoL). Methods: Data were drawn from the 2013 Diabetes Disease Specific 
Programme, a large cross-sectional real-world survey of primary care physicians 
(PCP) and specialists and their patients consulting for diabetes. Physicians pro-
vided information regarding prescriptions, previous treatment and most recent 
HbA1cvalues. Patients completed the Morisky Measurement of Adherence Scale 
and the EQ-5D. Patients who had been on current treatment between 6 months and 
5 years and had values for all variables were included. A linear Structural Equation 
Model was developed to explore the relationships between the number of oral and 
injectable diabetes medications per day, adherence, glycaemic control and QoL 
while adjusting for confounding factors relating to duration and type of medica-
tion, existing complications, concomitant conditions, demographic and lifestyle 
factors. Results: 239 PCPs and 137 specialists across 5 EU countries provided data 
on 1209 T2DM patients. 58% patients were male, mean age 60.7 years (+/-10.3); num-
ber of oral medications 2.21 (+/-1.16); injectables 0.36 (+/-1.03); current HbA1c6.94% 
(+/-0.80). The model shows that a lower number of daily diabetes medications is 
positively associated with adherence [orals (β = -0.10, p< 0.001), injectables (β = -0.049, 
p< 0.001)]. Improved adherence is associated with a lower HbA1c (β = -0.10, p< 0.001), 
lower HbA1cis associated with improved QoL (β = -0.019, p< 0.001). ConClusions: 
Controlling for important clinical and demographic factors, a lower number of daily 
glucose-lowering therapies is associated with greater adherence which, in turn, is 
associated with better glycaemic control and improved QoL. Further research is 
required to investigate if these associations vary depending on the specific medica-
tion taken or other patient-related parameters not considered here.
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polyNoMials – aN exaMple with fiRst liNe Metastatic ReNal cell 
caNceR tReatMeNts
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objeCtives: Summary survival data are available from published trials on first line 
metastatic renal cell cancer (1LmRCC) treatments. Survival on oncological treat-
ments in pharmacoeconomics is mainly estimated by fitting common parametric 
distributions over Kaplan Meier (KM) curves, assuming proportional hazards over 
time. Use of fractional polynomials (FP) allows for change of hazards over time and 
offers more freedom in distribution selection. This study aims to analyse exist-
ing survival data of 1LmRCC treatments through a network meta-analysis (NMA) 
and FP application. Methods: A systematic literature review was performed to 
identify randomized clinical trials (RCT) of 1LmRCC treatments with progression 
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objeCtives: Schizophrenia (SZ) is complex and multifactorial neuropsychiatric 
disorder.Schizophrenia is estimated to have the highest genetic and environ-
mental loads and penetrance among the neurocognitive disorders. The essential 
role dopamine D2 receptor (DRD2) in dopamine signalling, DRD2 gene has been 
regarded as one of the top candidate genes for SZ. The intention of this study was 
to evaluate the chromosomal aberrations as well as disruption in the DRD2 gene 
among the SZ patients. Methods: As a preliminary measure in the search for the 
chromosomal abnormalities of a gene or genes relevant to this illness, cytogenetic 
and molecular screenings using the Peripheral blood Lymphocyte of 45 SZ patients 
were obtained. Each patient were diagnosed by a neuropsychiatric professionals 
based on both DSM-IV(TR) and SCID questionnaire. Equal numbers of healthy 
controls were also analysed. Results: In our study random numerical and struc-
tural aberrations were detected in chromosomes 6, 11, 15, 16 and 22 (15q13.3 and 
22q11.2). In this study the comparison between the cases and control for the 
numerical as well as structural mutations showed a degree of (P< 0.001) which 
was more in cases compared to control. Structural aberrations predominantly 
observed were deletions and micro-deletions of 22q11.2 and 15q13.3. Further, 
the disruption in the DRD2 gene which resulted into polymorphism was seen in 
SZ patients while compared to healthy controls. ConClusions: In conclusion, 
our cohort study supports the hypothesis suggesting that a chromosomal abnor-
mality as well as disruption in DRD2 gene is contributing to SZ pathogenesis. 
On the contrary, genetics stimulate to rethink SZ from a neurological as well as 
biological viewpoint and also to understand the phenotypes of these disorder in 
terms of biological pathways. Key words: Schizophrenia, DRD2 gene, chromosomal 
abnormalities
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objeCtives: Melanoma is the fifth most common cancer in the UK, accounting for 
4% of all new cases of skin cancer. In 2011, 13,300 cases of malignant melanoma 
were diagnosed in the UK, out of which 2,200 people died from the disease. This 
systematic review evaluates the clinical effectiveness of VivaScope (MAVIG GmbH, 
Munich), a non-invasive reflectance confocal microscope (RCM), used following der-
moscopy for the diagnosis of melanoma. This research was conducted as part of 
a National Institute for Health and Care Excellence (NICE) Diagnostic Assessment 
Report on VivaScope. Methods: Electronic databases (MEDLINE, EMBASE and the 
Cochrane Library) were searched in October 2014 and updated in February 2015 to 
identify studies evaluating RCM following dermoscopy with histopathology as the 
reference standard in detecting malignant melanoma. Researchers were contacted 
for additional information on studies identified. Clinical experts were contacted 
for details on any unpublished studies. Results: Of the 7,446 studies identified 
in the literature search, 10 were considered relevant to this review. However, none 
were conducted in the UK (1 Spain, 1 China, 1 Australia, 2 Brazil/USA, 2 Australia/
Italy, 3 Italy) and the studies were considered too heterogeneous (e.g. differences in 
study design, patient/lesion level data, with/without comparator) for their results 
to be combined in a meta-analysis. Overall results indicate that RCM subsequent 
to dermoscopy may improve diagnostic accuracy of malignant melanomas com-
pared to dermoscopy alone. One study (Alarcon et al. 2014) was deemed to be most 
representative of UK clinical practice and reported statistically significant dif-
ferences in sensitivity (97.8% vs 94.6%, p= 0.043) and specificity (92.4% vs 26.74%, 
p< 0.000001), for VivaScope 1500 following dermoscopy compared with dermoscopy 
alone. ConClusions: VivaScope following dermoscopy may increase the accuracy 
of a diagnosis of malignant melanoma compared to dermoscopy alone. However, 
the absence of UK studies makes the generalisability of the results to UK clinical 
practice unclear.
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objeCtives: HPV genotypes 16/18 are the most prevalent worldwide and are 
present in around 70% of all cervical cancer (CxCa) cases. This analysis aims to 
estimate clinical and economic impact of the implementation of HPV 16/18 geno-
typing test for CxCa primary screening at Mexican Institute of Social Security 
(IMSS) that is the main healthcare provider covering around 50% of Mexican 
population. Methods: A cohort Markov model with a five-year time horizon 
was developed. A 300,000 women cohort was simulated since payer perspective. 
Two scenarios were evaluated: 1) cytology screening, where women are re-tested 
for ASCUS, ≥ CIN1 are referred to colposcopy, cycle lenght is 1-year, if negative 
3 consecutive cycles length changes to 2-years; 2) primary screening HPV gen-
otyping, women HPV-16/18 are referred to colposcopy, other 12 high-risk HVP 
genotyping are referred to cytology with 12-months follow-up, and when nega-
tive a follow-up in 3-year cycle. Clinical and test performance data were taken 
from ATHENA trial and other published sources. Direct medical costs for cytol-
ogy and CxCa treatments were obtained from local published sources. Costs for 
HPV genotyping test was given by the manufacturer. Costs are expressed in 2015 
USD ($1USD= $15MXN). Results: Due to cobas HPV genotyping sensibility, total 
number of CxCa cases would be 46% lower (221 vs 409, respectively) and would 
result in 44% less mortality events (8 vs 15, respectively) compared to cytology. To 
informatics, and Discrete Event Simulation (DES) known in operations research, 
for modeling todays complex and personalized treatment decisions over time, 
involving multiple interactions and decision gates. Methods: The usefulness of 
both modeling techniques was assessed in a case study on the treatment of meta-
static Castration Resistant Prostate Cancer (mCRPC) in which Circulating Tumor 
Cells (CTC) may be used as a response marker for switching first to second line 
treatment. Techniques were compared on user-friendliness, input requirements, 
input possibilities, model checking facilities, and results. Input parameters were 
similar for both models, consisting of costs, QoL, treatment effectiveness, diag-
nostic performance, physicians’ behavior and survival. Primary outcome meas-
ures were health outcomes, expressed in QALYs, and costs. Results: Modelling 
was considered easier using TA, as this approach allows independent modeling 
of the actors and elements comprising the treatment process, such as patients, 
physicians, tests and treatments, and their mutual interaction and communica-
tion. Furthermore, the statistical model checking feature in the TA software was 
found to be a powerful tool for validation. Input requirements and possibilities 
were similar for both modelling approaches in this case study. Both modelling 
approaches yield comparable results. Using TA, CTC reduced first and second line 
treatment by, on average, 108.9 and 107.6 days, respectively. Using DES, treatment 
was reduced by 83.6 and 85.0 days. CTC therefore reduced healthcare costs by 
€ 28,998 and € 21,992 according to TA and DES, respectively. ConClusions: Both 
Timed Automata and Discrete Event Simulation seem to be suitable for mod-
eling complex and personalized treatment processes like that of mCRPC. Timed 
Automata is a new and interesting alternative modeling technique, as it allows 
explicit separation of model components and supports statistical model checking 
to validate models.
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objeCtives: The safety and effectiveness of Thermal Massage Therapy for the 
Treatment of Dry Eye Syndrome as a technology for treatment of dry eye symptom 
by stimulation of the obstructed meibomian glands through application of heat and 
vibration to the areas around the eyelids and the eyes were assessed. Methods: 
For information search for systematic review considerations on Thermal Massage 
Therapy for the Treatment of Dry Eye Syndrome, 8 domestic databases including 
Korea Med and overseas databases including Ovid-Medline, Ovid-Embase and 
Cochrane Library were used. A total of 107 literatures were searched through search 
strategy. As the result, a total of 3 domestic and overseas literatures were included 
in the final assessment by applying the criteria for selection and exclusion to the 74 
literatures after having excluded 33 overlappingly searched literatures. Each of the 
stages from literature search to application of selection standards and extraction 
of data were carried out independently by 2 assessors under the deliberation by the 
Sub-committee. Tools of Scottish Intercollegiate Guidelines Network (SIGN) were 
used for assessment of the quality of literature. Results: Regarding the safety of 
the Thermal Massage Therapy for the Treatment of Dry Eye Syndrome, 3 literature 
reported conjunctivitis, temporary visual impairment, headache and abnormal-
ity in the area of contact as the procedure related complications or side effects. 
The effectiveness of the Thermal Massage Therapy for the Treatment of Dry Eye 
Syndrome was assessed by means of the ocular surface disease index (OSDI), break-
up time (BUT), schirmer tear test (STT) and osmotic pressure of tear on the basis of 
3 literatures. ConClusions: Thermal Massage Therapy for the Treatment of Dry 
Eye Syndrome was assessed as a safe and effective technology capable of improv-
ing the dry eye symptom by alleviating the obstructed meibomian glands through 
application of heat and vibration to the areas the eyes.
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objeCtives: The objective of this study was to examine the diagnostic accuracy 
of targeted sonomarkers in the first trimester for a simple screening method that 
improves outcome and has a positive cost/benefit ratio. Methods: We analyzed 23 
sonomarkers from 66 fetuses (6 cases of open spina bifida and 60 normal fetuses) 
to determine the most robust screening marker associated with spina bifida. We 
compared the variables between the two groups using Fisher’s exact test or Mann-
Whitney test. We evaluated the sensitivity with 5% FPR. We also performed receiver 
operating characteristic (ROC) curve analysis to determine which markers were 
significant to propose a simpler test. Results: Some markers showed statistically 
significant differences between the two groups (p< 0.001), but using both likelihood 
ratio and area under the ROC curve analysis, we demonstrated that the subjective 
Dry brain, Crush sign and BPD/AC ratio from axial views and numeric BS/BSOB ratio, 
FMF angle and Cisterna magna from sagittal views were significantly associated 
with the fetal risk of having OSB. ConClusions: Yet, subjective markers are usually 
dependent on the operator’s experience. Contrary, the measurement of the BPD/AC 
ratio or the BS/BSOB ratio at 11-13 weeks is simple and could be easily incorporated 
into the routine scan. If this test accurately predicts open spina bifida in up to 100% 
of cases, it would cost for one diagnostic 200 Ron= 44 Euro vs. the maternal serum 
alpha-fetoprotein test (250 Ron= 55 Euro) or amniocentesis (2000 Ron= 444 Euro) that 
are needed to early diagnosis of open spina bifida.
